PureTech affiliate resTORbio files for US IPO

Advanced, clinical-stage biopharmaceutical company PureTech Health issued an update on Tuesday, noting that resTORbio - an affiliate of PureTech Health - has previously confidentially submitted a draft registration statement with the United States Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

The company said the number of shares to be offered and the price range for the proposed offering had not yet been determined.

“The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions,” resTORbio’s board said in its own statement.